| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
144,540,000 |
| Market
Cap: |
123.83(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.8 - $2.24 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Akebia Therapeutics is a biopharmaceutical company. Co.'s portfolio includes a late-stage product candidate and a commercial product: Vadadustat, which is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability; and Auryxia® (ferric citrate), which is approved and marketed in the U.S. for two indications which are the control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis or the Hyperphosphatemia Indication, and the treatment of iron deficiency anemia (IDA) in adult patients with CKD not on dialysis or the IDA Indication.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
46,856 |
250,285 |
277,285 |
781,354 |
| Total Sell Value |
$59,038 |
$383,681 |
$414,731 |
$930,953 |
| Total People Sold |
2 |
4 |
4 |
5 |
| Total Sell Transactions |
2 |
12 |
13 |
28 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Satter Muneer A |
Director |
– • – |
2014-11-14 |
4 |
B |
$11.91 |
$59,550 |
I/I |
5,000 |
1,547,560 |
2.1 |
- |
|
| Satter Muneer A |
Director |
– • – |
2014-11-13 |
4 |
B |
$11.56 |
$57,800 |
I/I |
5,000 |
1,542,560 |
2.1 |
- |
|
| Gowen Maxine |
Director |
– • – |
2014-11-13 |
4 |
B |
$11.82 |
$15,365 |
D/D |
1,300 |
1,300 |
2.39 |
- |
|
| Satter Muneer A |
Director |
– • – |
2014-11-12 |
4 |
B |
$10.85 |
$59,515 |
I/I |
5,000 |
1,537,560 |
2.1 |
- |
|
| Butler John P. |
CEO and President |
• • – |
2014-11-12 |
4 |
B |
$10.31 |
$10,305 |
D/D |
1,000 |
45,350 |
2.81 |
- |
|
| Butler John P. |
CEO and President |
• • – |
2014-11-11 |
4 |
OE |
$0.47 |
$14,335 |
D/D |
30,500 |
44,350 |
|
- |
|
| Amello Jason |
SVP, CFO & Treasurer |
• – – |
2014-03-25 |
4 |
B |
$17.00 |
$68,000 |
D/D |
4,000 |
4,000 |
2.74 |
- |
|
| Satter Muneer A |
Director |
– • – |
2014-03-25 |
4 |
B |
$17.00 |
$1,552,015 |
I/I |
91,295 |
1,532,560 |
2.1 |
- |
|
| Satter Muneer A |
Director |
– • – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,441,265 |
1,441,265 |
|
- |
|
| Butler John P. |
President and CEO |
• • – |
2014-03-25 |
4 |
B |
$17.00 |
$235,450 |
D/D |
13,850 |
13,850 |
2.81 |
- |
|
| Shalwitz Robert |
Chief Medical Officer |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
I/I |
17,016 |
264,556 |
|
- |
|
| Shalwitz Robert |
Chief Medical Officer |
• – – |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,560 |
247,540 |
|
- |
|
| Hadas Nicole R. |
See Remarks |
• – – |
2014-03-25 |
4 |
B |
$17.00 |
$59,500 |
D/D |
3,500 |
76,123 |
2.74 |
- |
|
| Wyzga Michael S |
Director |
– • – |
2014-03-25 |
4 |
B |
$17.00 |
$25,500 |
D/D |
1,500 |
1,500 |
2.39 |
- |
|
| Novartis Bioventures Ltd |
10% Owner |
– – • |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,223,174 |
3,405,764 |
|
- |
|
| Novartis Bioventures Ltd |
10% Owner |
– – • |
2014-03-25 |
4 |
B |
$17.00 |
$3,104,030 |
D/D |
182,590 |
182,590 |
2.45 |
- |
|
| Novo A/s |
SEE REMARKS |
– – • |
2014-03-25 |
4 |
B |
$17.00 |
$3,104,030 |
D/D |
182,590 |
1,516,387 |
2.45 |
- |
|
| Novo A/s |
SEE REMARKS |
– – • |
2014-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,333,797 |
1,333,797 |
|
- |
|
| Nash Duane |
Director |
– • – |
2014-03-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
47,525 |
|
- |
|
| Hadas Nicole R. |
See RemarksOfficer |
• – – |
2014-03-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
72,623 |
|
- |
|
| Shalwitz Robert |
Chief Medical OfficerOfficer |
• – – |
2014-03-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
234,980 |
|
- |
|
271 Records found
|
|
Page 11 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (5.2%) 
